Active Not Recruiting
PHASE3
INTERVENTIONAL
NCT06221969
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Cagrilintide will be administered subcutaneously.
Name:
Semaglutide
Type:
DRUG
Description:
Semaglutide will be administered subcutaneously.
Name:
Tirzepatide
Type:
DRUG
Description:
Tirzepatide will be administered subcutaneously.
Primary Outcomes
Measure:
Change in glycated haemoglobin (HbA1c)
TimeFrame:
From baseline (week 0) to end of treatment (week 68)
Description:
Measured in percentage (%)-points.
Measure:
Relative change in body weight
TimeFrame:
From baseline (week 0) to end of treatment (week 68)
Description:
Measured in percentage (%).
Trial Information
NCT ID
NCT06221969
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025